{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:29:23Z","timestamp":1770438563571,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Health","award":["DOH89-TD-1035"],"award-info":[{"award-number":["DOH89-TD-1035"]}]},{"name":"Department of Health","award":["DOH97-TD-D-113-97009"],"award-info":[{"award-number":["DOH97-TD-D-113-97009"]}]},{"DOI":"10.13039\/501100001868","name":"National Science Council of Taiwan","doi-asserted-by":"crossref","award":["101-2314-B-002-117"],"award-info":[{"award-number":["101-2314-B-002-117"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.canep.2013.03.013","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T16:52:42Z","timestamp":1366649562000},"page":"385-389","source":"Crossref","is-referenced-by-count":20,"title":["Rosiglitazone is not associated with an increased risk of bladder cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Chin-Hsiao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2013.03.013_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00125-010-1987-2","article-title":"Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies","volume":"54","author":"Wotton","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.canep.2013.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2337\/dc11-0020","article-title":"Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System","volume":"34","author":"Li","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00125-008-1204-8","article-title":"Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006","volume":"52","author":"Tseng","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.canep.2013.03.013_bib0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/gut.2010.226522","article-title":"Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan","volume":"60","author":"Tseng","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.canep.2013.03.013_bib0025","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00125-011-2171-z","article-title":"Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan","volume":"54","author":"Tseng","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.canep.2013.03.013_bib0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.canep.2011.02.014","article-title":"Diabetes and urothelial cancer risk: the Multiethnic Cohort study","volume":"35","author":"Woolcott","year":"2011","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2013.03.013_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/annonc\/mdr334","article-title":"Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan","volume":"23","author":"Tseng","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canep.2013.03.013_bib0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.metabol.2011.11.015","article-title":"Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan","volume":"61","author":"Tseng","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.canep.2013.03.013_bib0045","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0050","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.canep.2010.06.001","article-title":"Diabetes, physical activity and breast cancer among Hispanic women","volume":"34","author":"Sanderson","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2013.03.013_bib0055","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.canep.2012.02.005","article-title":"The influence of antidiabetic medications on the development and progression of prostate cancer","volume":"36","author":"Hitron","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2013.03.013_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.canep.2011.05.013","article-title":"Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer","volume":"36","author":"Dong","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2013.03.013_bib0065","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.canep.2010.06.014","article-title":"A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer","volume":"34","author":"Hammarsten","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2013.03.013_bib0070","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2337\/dc11-0512","article-title":"Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis","volume":"34","author":"Zhang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00125-011-2429-5","article-title":"Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database","volume":"55","author":"Blin","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.canep.2013.03.013_bib0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2013.03.013_bib0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jfma.2011.10.003","article-title":"Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.canep.2013.03.013_bib0090","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.canep.2013.03.013_bib0100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/dc11-1449","article-title":"Pioglitazone and bladder cancer: a population-based study of Taiwanese","volume":"35","author":"Tseng","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0105","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.2337\/dc11-0627","article-title":"Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer","volume":"34","author":"Yang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0110","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2013.03.013_bib0115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2337\/dc10-1640","article-title":"Diabetes and risk of prostate cancer: a study using the National Health Insurance","volume":"34","author":"Tseng","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10590501.2012.735519","article-title":"Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies","volume":"30","author":"Tseng","year":"2012","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"10.1016\/j.canep.2013.03.013_bib0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3322\/caac.20077","article-title":"Bladder cancer in 2010: how far have we come?","volume":"60","author":"Jacobs","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canep.2013.03.013_bib0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000315883","article-title":"Confounding","volume":"116","author":"van Stralen","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.canep.2013.03.013_bib0135","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0140","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2013.03.013_bib0145","unstructured":"European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/09\/news_detail_001119.jsp&murl=menus\/news_and_events\/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false [accessed 25.02.12]."},{"key":"10.1016\/j.canep.2013.03.013_bib0150","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMp1011042","article-title":"Responding to an FDA warning\u2014geographic variation in the use of rosiglitazone","volume":"363","author":"Shah","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2013.03.013_bib0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/diacare.16.1.137","article-title":"Development of macrovascular diseases in non-insulin-dependent-diabetics in northern Taiwan: a four-year follow-up study","volume":"16","author":"Fu","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.canep.2013.03.013_bib0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan's new national health insurance program: genesis and experience so far","volume":"22","author":"Cheng","year":"2003","journal-title":"Health Aff (Millwood)"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782113000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782113000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T16:54:14Z","timestamp":1539708854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782113000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1877782113000465"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2013.03.013","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}